Not provided
Not provided
Not provided
Not provided
Not provided
Covid-19. Relocation of trainee/investigator. Covid-19.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to address the feasibility of a randomized, double masked, cross-over study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
The Primary Hypothesis is that such a study will be feasible as defined by subject adherence to study medication and study procedures and avoidance of other cannabinoid containing substances during the trial period as well as by ability to mask subjects and investigators to treatment assignment
Secondary hypotheses are:
Dronabinol will:
Reduce patient-reported pain interference Reduce patient-reported pain scores and change patient-reported pain quality. Reduce use of opioid pain medications. Improve patient-reported stiffness, nausea and vomiting, sleep, mood, anxiety, and social functioning.
Reduce markers of inflammation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dronabinol, Then Placebo | Experimental | Participants will take 2.5 mg of Dronabinol for 2 weeks, 1 week washout and then take 2 weeks of placebo (microcrystalline cellulos). Subjects will take up to 8 capsules daily of the treatment daily during each phase. |
|
| Placebo, Then Dronabinol | Experimental | Participants will take placebo (microcrystalline cellulos) for 2 weeks, 1 week washout and then take 2.5 mg of Dronabinol for 2 weeks. Subjects will take up to 8 capsules daily of the treatment daily during each phase. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dronabinol 2.5 MG | Drug | Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility will be defined by ability to mask patients and investigators to treatment assignment and adherence | Feasibility will be defined by ability to mask patients and investigators to treatment assignment and adherence which will be defined in 3 ways. | 1 year |
| Adherence | Adherence to study drug will be assessed with weekly pill counts and urine toxicology. | 1 year |
| Avoidance | Avoidance of other cannabinoid containing substances will also be defined using urine toxicology once at the end of each treatment period and once at the end of the wash out period. | 7 weeks |
| Adherence to other study proceedures | Adherence to other study procedures will be defined as percent of visits attended, percent of urine and serum studies collected and percent of patient reported outcomes and daily pain severity and pain unpleasentness journals returned. | 7 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Patient reported 7-day pain interference | The primary endpoint for this study will be second treatment week 7-day pain impact as measured by the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) 7-day pain impact domain. ASCQ-Me domains are validated to measure pain and other quality of life outcomes in adults with Sickle Cell Disease (SCD) of all genotypes. The published mean for the validated scores is 50 and the standard deviation is 10.56 Lower scores represent more severe symptoms. When the validation cohort was placed into tertiles of severity, the tertile with most severe disease had a mean pain score of 53, the middle tertile had a score of 49, and the least severe disease tertile had a mean score of 46. This suggests that a change of 4 has clinical significance and a change of 7 has even more clinical significance. We have chosen a priori to define a difference in pain impact score of 5 points as showing superiority. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Susanna Curtis, MD | Yale University School of Medicine Oncology Section | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale New Haven Hospital Smilow Cancer Center | New Haven | Connecticut | 06510 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41225660 | Derived | Curtis SA, Jhawar R, Bellis J, McCuskee S, Devine L, Roberts JD. A pilot study of dronabinol for the treatment of pain in sickle cell disease. Pilot Feasibility Stud. 2025 Nov 12;11(1):139. doi: 10.1186/s40814-025-01705-6. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000755 | Anemia, Sickle Cell |
| ID | Term |
|---|---|
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013759 | Dronabinol |
| C109691 | microcrystalline cellulose |
| ID | Term |
|---|---|
| D002186 | Cannabinoids |
| D013729 | Terpenes |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided
This is a randomized, double blind, cross-over study of dronabinol compared to placebo
Not provided
Not provided
double blinded
| Microcrystalline cellulose | Drug | Subjects will take placebo daily during 2 week dosing period separated by a one week washout period. |
|
|
| 7 days |
| Patient Pain Severity | Daily reports of pain severity on a numeric rating scale of 0-10 with 0 representing the least severe pain (no pain) and 10 representing the most severe pain. | end of 2nd week |
| Patient Pain Unpleasantness | Daily reports of pain unpleasantness on a numeric rating scale of 0-10 with 0 representing the least pain unpleasantness (no unpleasantness) and 10 representing the most unpleasant pain. | end of 2nd week |
| PROMIS (Patient Reported Outcomes Measurement Information System) Nociceptive Pain Severity | Nociceptive pain quality as defined by the patient report outcome measurement information system (PROMIS) nociceptive pain quality 5a scale. All PROMIS scores will be presented as T scores. The T score is a standardized score with a mean of 50 and a standard deviation of 10. The value of 50 represents the score of the average field test respondent. | end of 2nd week |
| PROMIS Neuropathic Pain Severity | Neuropathic pain quality as defined by the patient report outcome measurement information system (PROMIS) neuropathic pain quality 5a scale.All PROMIS scores will be presented as T scores. The T score is a standardized score with a mean of 50 and a standard deviation of 10. The value of 50 represents the score of the average field test respondent. | end of 2nd week |
| PROMIS Gastrointestinal Nausea short form measure | PROMIS short form Gastrointestinal Nausea and vomiting 4a. All PROMIS scores will be presented as T scores. The T score is a standardized score with a mean of 50 and a standard deviation of 10. The value of 50 represents the score of the average field test respondent. | end of 2nd week |
| PROMIS short form for emotional distress anxiety 8a. | PROMIS short form Gastrointestinal Nausea and vomiting 4a. All PROMIS scores will be presented as T scores. The T score is a standardized score with a mean of 50 and a standard deviation of 10. The value of 50 represents the score of the average field test respondent. | end of 2nd week |
| Adult Sickle Cell Quality (ASCQ)-Me short form measures of emotional impact | Each ASCQ-Me score is reported on the same standardized scale with a mean of 50 and a standard deviation of 10. The value of 50 represents the health score of the average field test respondent. | end of 2nd week |
| Adult Sickle Cell Quality (ASCQ)-Me short form measure of sleep impact | Each ASCQ-Me score is reported on the same standardized scale with a mean of 50 and a standard deviation of 10. The value of 50 represents the health score of the average field test respondent. | end of 2nd week |
| Adult Sickle Cell Quality (ASCQ)-Me short form measure of stiffness impact | Each ASCQ-Me score is reported on the same standardized scale with a mean of 50 and a standard deviation of 10. The value of 50 represents the health score of the average field test respondent. | end of 2nd week |
| Adult Sickle Cell Quality (ASCQ)-Me short form measure of social functioning impact | Each ASCQ-Me score is reported on the same standardized scale with a mean of 50 and a standard deviation of 10. The value of 50 represents the health score of the average field test respondent. | end of 2nd week |
| Opioid Utilization | Secondary comparisons will be made between subjects on dronabinol to themselves on placebo for patient reported outcomes for opioid use. Opioid utilization will be based on reports of opioids dispensed obtained from the Connecticut Prescription Monitoring Program. Reports will be in the form of average daily opioids used in oral morphine equivalents. | end of 2nd week |
| Markers of Inflammation Concentration of white blood cell count differential | Secondary comparisons will be made between subjects on dronabinol to themselves on placebo for differential white blood cell count at the end of the second week of the treatment period. | end of 2nd week |
| Markers of Inflammation C reactive protein | Secondary comparisons will be made between subjects on dronabinol to themselves on placebo of C reactive protein at the end of the second week of the treatment period. | end of 2nd week |
| Markers of Inflammation serum tryptase | Secondary comparisons will be made between subjects on dronabinol to themselves on placebo for serum tryptase at the end of the second week of the treatment period. | end of 2nd week |
| Serum pro-inflammatory cytokines | Secondary comparisons will be made between subjects on dronabinol to themselves on placebo for pro-inflammatory cytokines at the end of the second week of the treatment period. | end of 2nd week |
| Serum measure of Substance P | Secondary comparisons will be made between subjects on dronabinol to themselves on placebo for Substance P at the end of the second week of the treatment period. | end of 2nd week |
| D006425 |
| Hemic and Lymphatic Diseases |
| D006453 | Hemoglobinopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |